Concord Biotech Limited delivered robust financial results for the first quarter of FY27, reporting a consolidated net profit (PAT) of ₹57.7 crore, a 31% increase from ₹44.1 crore in Q1FY26. The growth was underpinned by a 26% rise in revenue from operations to ₹257.5 crore, reflecting broad-based demand across its Active Pharmaceutical Ingredients (API) and formulation segments. This performance signals strengthening market share and operational efficiency for the biopharma firm.

The company filed its unaudited standalone and consolidated financial results with the National Stock Exchange of India Limited and BSE Limited on August 01, 2026, pursuant to Regulation 30 and Schedule III Part A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The filing was signed by Paritosh Trivedi, Company Secretary and Compliance Officer.

Financial Performance Breakdown

Revenue growth was primarily driven by the API segment, which saw a 42% year-on-year increase to ₹218.9 crore from ₹153.8 crore in Q1FY26. In contrast, formulation revenue declined 23% to ₹38.6 crore from ₹50.2 crore. Geographically, export revenue surged 46% to ₹121.7 crore, significantly outpacing domestic revenue growth of 12% to ₹135.8 crore.

Excluding the impact of the injectable facility and expenses related to Stellon Biotech, EBITDA margins stood at 37% for Q1FY27. Cost of goods sold increased to ₹54 crore from ₹45 crore, while employee costs rose to ₹44 crore from ₹38 crore.

Operational Highlights

Ankur Vaid, Joint Managing Director & Chief Executive Officer, attributed the performance to increased wallet share among existing customers and the addition of new products. The company noted advanced discussions with large customers and a robust pipeline targeting 2-3 product launches annually. Regulatory milestones included USFDA approvals for Abbreviated New Drug Applications (ANDAs) for Mycophenolate Mofetil and Tofacitinib Tablets.

The company also completed inspections by ANVISA at its Limbasi facility and by the Pharmacy and Poisons Board (PPB) of Kenya and the National Drug Authority (NDA) of Uganda at its Unit-II formulation facility. Additionally, Concord Biotech received a Silver Medal from EcoVadis, placing it among the top 15% of companies assessed globally for sustainability.

What the Numbers Show

The divergence between API and formulation revenue highlights a strategic shift or temporary headwind in the latter segment. While API revenue surged 42%, formulation revenue contracted 23%. However, the overall margin expansion—EBITDA margins up 190 basis points—suggests that the higher-margin API mix is driving profitability despite the volume drop in formulations. The 46% export growth further indicates successful penetration into regulated international markets, reducing reliance on domestic demand.

Concord Biotech Limited shareholders approved all six resolutions tabled at its 41st Annual General Meeting (AGM) held on July 31, 2026, including a critical special resolution to expand lending capabilities to its group companies. The approval of enhanced limits for advancing loans, providing guarantees, and securities to subsidiaries, associates, and joint venture companies marks a key strategic move for the biotechnology firm, enabling greater financial flexibility within its corporate structure pursuant to Section 185 of the Companies Act, 2013.

The meeting, conducted via Video Conferencing/Other Audio Visual Means (VC/OAVM), saw substantial participation through remote e-voting. Ashish Shah of Ashish Shah & Associates served as the scrutinizer for the proceedings, submitting his consolidated report on July 31, 2026, in compliance with Section 108 of the Companies Act, 2013 and Rule 20(xi) of the Companies (Management and Administration) Rules, 2014. Central Depository Services (India) Limited (CDSL) facilitated the remote e-voting process, which remained open from July 28, 2026, to July 30, 2026.

Voting Results Overview

A total of 83,770 shareholders were on record as of July 24, 2026. While no shareholders attended in person or via proxy, 38 shareholders participated through VC/OAVM (four promoters and 34 public shareholders). The majority of votes were cast electronically.

Key Observations on Shareholder Sentiment

The most notable divergence in shareholder sentiment occurred regarding the special resolution for enhanced loan limits. Promoter and promoter group shareholders, holding 46,116,608 shares, abstained from voting on this item, citing their interest in the agenda. Consequently, the resolution relied entirely on public shareholder support. Public non-institutional shareholders voted overwhelmingly in favor with 99.99% support, while public institutional shareholders showed mixed sentiment, with only 43.40% voting in favor and 56.60% against. Despite this institutional resistance, the resolution passed with 35,391,774 votes in favor out of 43,353,536 valid votes polled.

In contrast, other resolutions enjoyed near-unanimous support. The adoption of the standalone and consolidated financial statements for the financial year ended March 31, 2026, received 99.69% support. The declaration of dividend was approved with 99.98% affirmative votes. The re-appointment of Mr. Ankur Vaid (DIN: 01857225), who retires by rotation, secured 99.70% support. Similarly, the appointment of Mrs. Ekta Gupta as an independent director was approved with virtually unanimous consent, receiving negligible opposition.